Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Henderson Morley, a vaccine and anti-viral drug development company has announced positive results of studies that examined safety, antigenicity and immunogenicity of PREPS and L-particles in laboratory models.
Subscribe to our email newsletter
PREPS and L-particles were demonstrated to be stable, safe, and well tolerated. The studies also demonstrated that a potent and dose related immune response was generated to the target antigen. These positive results will now lead to further studies examining engineered PREPS and L-particles targeted at either cancer or other model antigens. These studies will aid the further development of PREPS and L-particles as cancer immunotherapeutic candidates. The studies will also aide with identification and selection of lead candidate vaccines.
These technologies are being developed to target a number of important diseases including virus infections in humans such as cytomegalovirus, Epstein Barr virus and herpes simplex virus, and as a cancer immunotherapy for a wide range of different forms of human and animal cancers.